Abstract
Mood disorders, such as bipolar and major depressive disorders, are frequent, severe, and often disabling neuropsychiatric diseases affecting millions of individuals worldwide. Available mood stabilizers and antidepressants remain unsatisfactory because of their delayed and partial therapeutic efficacy. Therefore, the development of targeted therapies, working more rapidly and being fully effective, is urgently needed. In this context, the protein kinase C (PKC) signaling system, which regulates multiple neuronal processes implicated in mood regulation, can constitute a novel therapeutic target. This paper reviews the currently available knowledge regarding the role of the PKC signaling pathway in the pathophysiology of mood disorders and the therapeutic potential of PKC modulators. Current antidepressants and mood stabilizers have been shown to modulate the PKC pathway, and the inhibition of this intracellular signaling cascade results in antimanic-like properties in animal models. Disrupted PKC activity has been found both in postmortem brains and platelet from patients with mood disorders. Finally, the PKC inhibitor tamoxifen has recently demonstrated potent antimanic properties in several clinical trials. Overall, emerging data from preclinical and clinical research suggest an imbalance of the PKC signaling system in mood disorders. Thus, PKC may be a critical molecular target for the development of innovative therapeutics.
Similar content being viewed by others
References
Kessler RC, Chiu WT, Demler O, Walters EE (2005) Prevalence, Severity, and Comorbidity of 12-Month DSM-IV Disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62:617–627. doi:10.1001/archpsyc.62.6.617
American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders (Revised 4th edn). American Psychiatric Association, Washington, DC
Frye MA (2011) Clinical practice. Bipolar disorder–a focus on depression. N Engl J Med 364:51–59. doi:10.1056/NEJMcp1000402
Blier P, de Montigny C (1999) Serotonin and drug-induced therapeutic responses in major depression, obsessive-compulsive and panic disorders. Neuropsychopharmacology 21:91S–98S. doi:10.1016/S0893-133X(99)00036-6
Faure C, Mnie-Filali O, Haddjeri N (2006) Long-term adaptive changes induced by serotonergic antidepressant drugs. Expert Rev Neurother 6:235–245. doi:10.1586/14737175.6.2.235
Chen J, Fang Y, Kemp DE et al (2010) Switching to hypomania and mania: differential neurochemical, neuropsychological, and pharmacologic triggers and their mechanisms. Curr Psychiatry Rep 12:512–521. doi:10.1007/s11920-010-0157-z
Rapoport SI, Basselin M, Kim H-W, Rao JS (2009) Bipolar disorder and mechanisms of action of mood stabilizers. Brain Res Rev 61:185–209. doi:10.1016/j.brainresrev.2009.06.003
Zarate C, Machado-Vieira R, Henter I et al (2010) Glutamatergic modulators: the future of treating mood disorders? Harv Rev Psychiatry 18:293–303. doi:10.3109/10673229.2010.511059
Castrén E (2005) Is mood chemistry? Nat Rev Neurosci 6:241–246. doi:10.1sj.npp./nrn1629
Pittenger C, Duman RS (2008) Stress, depression, and neuroplasticity: a convergence of mechanisms. Neuropsychopharmacology 33:88–109. doi:10.1sj.npp./sj.npp.1301574
Drevets WC (2001) Neuroimaging and neuropathological studies of depression: implications for the cognitive-emotional features of mood disorders. Curr Opin Neurobiol 11:240–249. doi:10.1016/S0959-4388(00)00203-8
Artigas F, Nutt DJ, Shelton R (2002) Mechanism of action of antidepressants. Psychopharmacol Bull 36(Suppl 2):123–132
Tanis KQ, Duman RS (2007) Intracellular signaling pathways pave roads to recovery for mood disorders. Ann Med 39:531–544. doi:10.1080/07853890701483270
Ohno S, Nishizuka Y (2002) Protein kinase C isotypes and their specific functions: prologue. J Biochem 132:509–511
Wetsel WC, Khan WA, Merchenthaler I et al (1992) Tissue and cellular distribution of the extended family of protein kinase C isoenzymes. J Cell Biol 117:121–133
Naik MU, Benedikz E, Hernandez I et al (2000) Distribution of protein kinase Mzeta and the complete protein kinase C isoform family in rat brain. J Comp Neurol 426:243–258
Tanaka C, Saito N (1992) Localization of subspecies of protein kinase C in the mammalian central nervous system. Neurochem Int 21:499–512
Amadio M, Battaini F, Pascale A (2006) The different facets of protein kinases C: old and new players in neuronal signal transduction pathways. Pharmacol Res 54:317–325. doi:10.1016/j.phrs.2006.08.002
Boehm J, Kang M-G, Johnson RC et al (2006) Synaptic Incorporation of AMPA Receptors during LTP Is Controlled by a PKC Phosphorylation Site on GluR1. Neuron 51:213–225. doi:10.1016/j.neuron.2006.06.013
Dai S, Hall DD, Hell JW (2009) Supramolecular assemblies and localized regulation of voltage-gated ion channels. Physiol Rev 89:411–452. doi:10.1152/physrev.00029.2007
Goode N, Hughes K, Woodgett JR, Parker PJ (1992) Differential regulation of glycogen synthase kinase-3 beta by protein kinase C isotypes. J Biol Chem 267:16878–16882
Huang K-P (1989) The mechanism of protein kinase C activation. Trends Neurosci 12:425–432. doi:10.1016/0166-2236(89)90091-X
Jayanthi LD, Samuvel DJ, Blakely RD, Ramamoorthy S (2005) Evidence for biphasic effects of protein kinase C on serotonin transporter function, endocytosis, and phosphorylation. Mol Pharmacol 67:2077–2087. doi:10.1124/mol.104.009555
Kolch W, Heidecker G, Kochs G et al (1993) Protein kinase C alpha activates RAF-1 by direct phosphorylation. Nature 364:249–252. doi:10.1sj.npp./364249a0
Martelli AM, Evangelisti C, Nyakern M, Manzoli FA (2006) Nuclear protein kinase C. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 1761:542–551. doi:10.1016/j.bbalip.2006.02.009
Morgan A, Burgoyne RD, Barclay JW et al (2005) Regulation of exocytosis by protein kinase C. Biochem Soc Trans 33:1341–1344. doi:10.1042/BST20051341
Pasinelli P, Ramakers GM, Urban IJ et al (1995) Long-term potentiation and synaptic protein phosphorylation. Behav Brain Res 66:53–59
Yoshimasa T, Sibley DR, Bouvier M et al (1987) Cross-talk between cellular signalling pathways suggested by phorbol-ester-induced adenylate cyclase phosphorylation. Nature 327:67–70. doi:10.1sj.npp./327067a0
Hofmann J (1997) The potential for isoenzyme-selective modulation of protein kinase C. FASEB J 11:649–669
Nelson TJ, Alkon DL (2009) Neuroprotective versus tumorigenic protein kinase C activators. Trends Biochem Sci 34:136–145. doi:10.1016/j.tibs.2008.11.006
Ron D, Kazanietz MG (1999) New insights into the regulation of protein kinase C and novel phorbol ester receptors. FASEB J 13:1658–1676
Bitran JA, Manji HK, Potter WZ, Gusovsky F (1995) Down-regulation of PKC alpha by lithium in vitro. Psychopharmacol Bull 31:449–452
Manji HK, Lenox RH (1999) Ziskind-Somerfeld Research Award. Protein kinase C signaling in the brain: molecular transduction of mood stabilization in the treatment of manic-depressive illness. Biol Psychiatry 46:1328–1351
Manji HK, Etcheberrigaray R, Chen G, Olds JL (1993) Lithium decreases membrane-associated protein kinase C in hippocampus: selectivity for the alpha isozyme. J Neurochem 61:2303–2310
Jensen JB, Mørk A (1997) Altered protein phosphorylation in the rat brain following chronic lithium and carbamazepine treatments. Eur Neuropsychopharmacol 7:173–179
Lenox RH, Watson DG, Patel J, Ellis J (1992) Chronic lithium administration alters a prominent PKC substrate in rat hippocampus. Brain Res 570:333–340
Szabo ST, Machado-Vieira R, Yuan P et al (2009) Glutamate receptors as targets of protein kinase C in the pathophysiology and treatment of animal models of mania. Neuropharmacology 56:47–55. doi:10.1016/j.neuropharm.2008.08.015
Chen G, Manji HK, Hawver DB et al (1994) Chronic sodium valproate selectively decreases protein kinase C alpha and epsilon in vitro. J Neurochem 63:2361–2364
Basta-Kaim A, Budziszewska B, Jaworska-Feil L et al (2006) Antipsychotic drugs inhibit the human corticotropin-releasing-hormone gene promoter activity in neuro-2A cells-an involvement of protein kinases. Neuropsychopharmacology 31:853–865. doi:10.1038/sj.npp.1300911
Moore GJ, Bebchuk JM, Parrish JK et al (1999) Temporal dissociation between lithium-induced changes in frontal lobe myo-inositol and clinical response in manic-depressive illness. Am J Psychiatry 156:1902–1908
Mann CD, Vu TB, Hrdina PD (1995) Protein kinase C in rat brain cortex and hippocampus: effect of repeated administration of fluoxetine and desipramine. Br J Pharmacol 115:595–600
Rausch JL, Gillespie CF, Fei Y et al (2002) Antidepressant effects on kinase gene expression patterns in rat brain. Neurosci Lett 334:91–94
Kim SH, Kim MK, Yu HS et al (2010) Electroconvulsive seizure increases phosphorylation of PKC substrates, including GAP-43, MARCKS, and neurogranin, in rat brain. Prog Neuropsychopharmacol Biol Psychiatry 34:115–121. doi:10.1016/j.pnpbp. 2009.10.009
Nestler EJ, Hyman SE (2010) Animal models of neuropsychiatric disorders. Nat Neurosci 13:1161–1169. doi:10.1sj.npp./nn.2647
Frey BN, Valvassori SS, Réus GZ et al (2006) Effects of lithium and valproate on amphetamine-induced oxidative stress generation in an animal model of mania. J Psychiatry Neurosci 31:326–332
Wesołowska A, Partyka A, Jastrzębska-Więsek M et al (2010) Tail suspension test does not detect antidepressant-like properties of atypical antipsychotics. Behav Pharmacol. doi:10.1097/FBP.0b013e3283423d6b
Abrial E, Etievant A, Bétry C et al (2011) Manic-like response to amphetamine or sleep deprivation in rats is decreased by protein kinase C inhibition. 10th Meeting of Société des Neurosciences, Marseille, France, May 24–27, 2011
Einat H, Yuan P, Szabo ST et al (2007) Protein kinase C inhibition by tamoxifen antagonizes manic-like behavior in rats: implications for the development of novel therapeutics for bipolar disorder. Neuropsychobiology 55:123–131. doi:10.1159/000106054
Sabioni P, Baretta IP, Ninomiya EM et al (2008) The antimanic-like effect of tamoxifen: Behavioural comparison with other PKC-inhibiting and antiestrogenic drugs. Prog Neuropsychopharmacol Biol Psychiatry 32:1927–1931. doi:10.1016/j.pnpbp.2008.09.023
Browman KE, Kantor L, Richardson S et al (1998) Injection of the protein kinase C inhibitor Ro31-8220 into the nucleus accumbens attenuates the acute response to amphetamine: tissue and behavioral studies. Brain Res 814:112–119
Steketee JD (1993) Injection of the protein kinase inhibitor H7 into the A10 dopamine region blocks the acute responses to cocaine: behavioral and in vivo microdialysis studies. Neuropharmacology 32:1289–1297
Kantor L, Gnegy ME (1998) Protein kinase C inhibitors block amphetamine-mediated dopamine release in rat striatal slices. J Pharmacol Exp Ther 284:592–598
Loweth JA, Svoboda R, Austin JD et al (2009) The PKC inhibitor Ro31-8220 blocks acute amphetamine-induced dopamine overflow in the nucleus accumbens. Neurosci Lett 455:88–92. doi:10.1016/j.neulet.2009.03.012
Chen R, Furman CA, Zhang M et al (2009) Protein kinase Cbeta is a critical regulator of dopamine transporter trafficking and regulates the behavioral response to amphetamine in mice. J Pharmacol Exp Ther 328:912–920. doi:10.1124/jpet.108.147959
Gessa GL, Pani L, Fadda P, Fratta W (1995) Sleep deprivation in the rat: an animal model of mania. Eur Neuropsychopharmacol 5(Suppl):89–93
Einat H, Manji HK (2006) Cellular Plasticity Cascades: Genes-To-Behavior Pathways in Animal Models of Bipolar Disorder. Biol Psychiatry 59:1160–1171. doi:10.1016/j.biopsych.2005.11.004
Cervo L, Mukherjee S, Bertaglia A, Samanin R (1997) Protein kinases A and C are involved in the mechanisms underlying consolidation of cocaine place conditioning. Brain Res 775:30–36
Lai Y-T, Fan H-Y, Cherng CG et al (2008) Activation of amygdaloid PKC pathway is necessary for conditioned cues-provoked cocaine memory performance. Neurobiol Learn Mem 90:164–170. doi:10.1016/j.nlm.2008.03.006
Narita M, Akai H, Nagumo Y et al (2004) Implications of protein kinase C in the nucleus accumbens in the development of sensitization to methamphetamine in rats. Neuroscience 127:941–948. doi:10.1016/j.neuroscience.2004.06.017
Narita M, Aoki T, Ozaki S et al (2001) Involvement of protein kinase Cgamma isoform in morphine-induced reinforcing effects. Neuroscience 103:309–314
Olive MF, Mehmert KK, Messing RO, Hodge CW (2000) Reduced operant ethanol self-administration and in vivo mesolimbic dopamine responses to ethanol in PKCepsilon-deficient mice. Eur J Neurosci 12:4131–4140
Abrial E, Haddjeri N, Lambás-Señas L (2010) Effects of protein kinase c inhibitors tamoxifen and chelerythrine on anxiety and depression-like behaviors. FENS Abstr. vol. 5
Raygada M, Cho E, Hilakivi-Clarke L (1998) High maternal intake of polyunsaturated fatty acids during pregnancy in mice alters offsprings’ aggressive behavior, immobility in the swim test, locomotor activity and brain protein kinase C activity. J Nutr 128:2505–2511
Birnbaum SG, Yuan PX, Wang M et al (2004) Protein kinase C overactivity impairs prefrontal cortical regulation of working memory. Science 306:882–884. doi:10.1126/science.1100021
Hains AB, Vu MAT, Maciejewski PK et al (2009) Inhibition of protein kinase C signaling protects prefrontal cortex dendritic spines and cognition from the effects of chronic stress. Proc Natl Acad Sci U S A 106:17957–17962. doi:10.1073/pnas.0908563106
Palumbo ML, Zorrilla Zubilete MA, Cremaschi GA, Genaro AM (2009) Different effect of chronic stress on learning and memory in BALB/c and C57BL/6 inbred mice: Involvement of hippocampal NO production and PKC activity. Stress 12:350–361. doi:10.1080/10253890802506383
Park S-H, Choi S-H, Lee J et al (2008) Effects of repeated citalopram treatments on chronic mild stress-induced growth associated protein-43 mRNA expression in rat hippocampus. Korean J Physiol Pharmacol 12:117–123. doi:10.4196/kjpp.2008.12.3.117
Han F, Shioda N, Moriguchi S et al (2008) Spiro[imidazo[1,2-a]pyridine-3,2-indan]-2(3H)-one (ZSET1446/ST101) treatment rescues olfactory bulbectomy-induced memory impairment by activating Ca2+/calmodulin kinase II and protein kinase C in mouse hippocampus. J Pharmacol Exp Ther 326:127–134. doi:10.1124/jpet.108.137471
Moriguchi S, Han F, Nakagawasai O et al (2006) Decreased calcium/calmodulin-dependent protein kinase II and protein kinase C activities mediate impairment of hippocampal long-term potentiation in the olfactory bulbectomized mice. J Neurochem 97:22–29. doi:10.1111/j.1471-4159.2006.03710.x
Dwivedi Y, Mondal AC, Rizavi HS et al (2005) Single and repeated stress-induced modulation of phospholipase C catalytic activity and expression: role in LH behavior. Neuropsychopharmacology 30:473–483. doi:10.1038/sj.npp. 1300605
Wu J, Song T-B, Li Y-J et al (2007) Prenatal restraint stress impairs learning and memory and hippocampal PKCbeta1 expression and translocation in offspring rats. Brain Res 1141:205–213. doi:10.1016/j.brainres.2007.01.024
Alfonso J, Frick LR, Silberman DM et al (2006) Regulation of Hippocampal Gene Expression Is Conserved in Two Species Subjected to Different Stressors and Antidepressant Treatments. Biol Psychiatry 59:244–251. doi:10.1016/j.biopsych.2005.06.036
Zheng H, Ma G-yu, Fu X-chun, DU H-guang (2008) Effects of paroxetine on protein kinase PKA, PKC and CaMKII activity in different brain regions in a rat depression model. Nan Fang Yi Ke Da Xue Xue Bao 28:1223–1225
Lueptow LM, Zhao Z, O’Donnell JM (2010) Norepinephrine and serotonin transporter regulation is important for antidepressant-like effects on behavior in rats. SFN abstr. 2010
Sun M-K, Alkon DL (2005) Dual effects of bryostatin-1 on spatial memory and depression. Eur J Pharmacol 512:43–51. doi:10.1016/j.ejphar.2005.02.028
Baum AE, Akula N, Cabanero M et al (2008) A genome-wide association study implicates diacylglycerol kinase eta (DGKH) and several other genes in the etiology of bipolar disorder. Mol Psychiatry 13:197–207. doi:10.1038/sj.mp.4002012
Burton PR, Clayton DG, Cardon LR (2007) Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447:661–678. doi: 10.1sj.npp./nature05911
Turecki G, Grof P, Cavazzoni P et al (1998) Evidence for a role of phospholipase C-gamma1 in the pathogenesis of bipolar disorder. Mol Psychiatry 3:534–538
Ohnishi T, Yamada K, Ohba H et al (2007) A promoter haplotype of the inositol monophosphatase 2 gene (IMPA2) at 18p11.2 confers a possible risk for bipolar disorder by enhancing transcription. Neuropsychopharmacology 32:1727–1737. doi:10.1038/sj.npp.1301307
Sjøholt G, Ebstein RP, Lie RT et al (2004) Examination of IMPA1 and IMPA2 genes in manic-depressive patients: association between IMPA2 promoter polymorphisms and bipolar disorder. Mol Psychiatry 9:621–629. doi:10.1038/sj.mp.4001460
Pandey GN, Dwivedi Y, Pandey SC et al (1997) Protein kinase C in the postmortem brain of teenage suicide victims. Neurosci Lett 228:111–114
Pandey GN, Dwivedi Y, Rizavi HS et al (2004) Decreased catalytic activity and expression of protein kinase C isozymes in teenage suicide victims: a postmortem brain study. Arch Gen Psychiatry 61:685–693. doi:10.1001/archpsyc.61.7.685
Wang HY, Friedman E (1996) Enhanced protein kinase C activity and translocation in bipolar affective disorder brains. Biol Psychiatry 40:568–575
Jope RS, Song L, Li PP et al (1996) The phosphoinositide signal transduction system is impaired in bipolar affective disorder brain. J Neurochem 66:2402–2409
Mathews R, Li PP, Young LT et al (1997) Increased G alpha q/11 immunoreactivity in postmortem occipital cortex from patients with bipolar affective disorder. Biol Psychiatry 41:649–656. doi:10.1016/S0006-3223(96)00113-8
Shelton RC, Hal Manier D, Lewis DA (2009) Protein kinases A and C in post-mortem prefrontal cortex from persons with major depression and normal controls. Int J Neuropsychopharmacol 12:1223–1232. doi:10.1017/S1461145709000285
Pandey GN, Dwivedi Y, Ren X et al (2003) Altered expression and phosphorylation of myristoylated alanine-rich C kinase substrate (MARCKS) in postmortem brain of suicide victims with or without depression. J Psychiatr Res 37:421–432
Ohmori S, Sakai N, Shirai Y et al (2000) Importance of protein kinase C targeting for the phosphorylation of its substrate, myristoylated alanine-rich C-kinase substrate. J Biol Chem 275:26449–26457. doi:10.1074/jbc.M003588200
Wang HY, Markowitz P, Levinson D et al (1999) Increased membrane-associated protein kinase C activity and translocation in blood platelets from bipolar affective disorder patients. J Psychiatr Res 33:171–179
Friedman E, Wang HY, Levinson D et al (1993) Altered platelet protein kinase C activity in bipolar affective disorder, manic episode. Biol Psychiatry 33:520–525
Hahn C-G, Umapathy C, Wang H-Y et al (2005) Lithium and valproic acid treatments reduce PKC activation and receptor-G protein coupling in platelets of bipolar manic patients. J Psychiatr Res 39:355–363
Pandey GN, Ren X, Dwivedi Y, Pavuluri MN (2008) Decreased protein kinase C (PKC) in platelets of pediatric bipolar patients: effect of treatment with mood stabilizing drugs. J Psychiatr Res 42:106–116. doi:10.1016/j.jpsychires.2006.11.004
Young LT, Wang JF, Woods CM, Robb JC (1999) Platelet protein kinase C alpha levels in drug-free and lithium-treated subjects with bipolar disorder. Neuropsychobiology 40:63–66
Pandey GN, Dwivedi Y, SridharaRao J et al (2002) Protein kinase C and phospholipase C activity and expression of their specific isozymes is decreased and expression of MARCKS is increased in platelets of bipolar but not in unipolar patients. Neuropsychopharmacology 26:216–228. doi:10.1016/S0893-133X(01)00327-X
Bebchuk JM, Arfken CL, Dolan-Manji S et al (2000) A preliminary investigation of a protein kinase C inhibitor in the treatment of acute mania. Arch Gen Psychiatry 57:95–97
Amrollahi Z, Rezaei F, Salehi B et al (2010) Double-blind, randomized, placebo-controlled 6-week study on the efficacy and safety of the tamoxifen adjunctive to lithium in acute bipolar mania. J Affect Disord 129:327–331. doi:10.1016/j.jad.2010.08.015
Kulkarni J, Garland KA, Scaffidi A et al (2006) A pilot study of hormone modulation as a new treatment for mania in women with bipolar affective disorder. Psychoneuroendocrinology 31:543–547. doi:10.1016/j.psyneuen.2005.11.001
Yildiz A, Guleryuz S, Ankerst DP et al (2008) Protein kinase C inhibition in the treatment of mania: a double-blind, placebo-controlled trial of tamoxifen. Arch Gen Psychiatry 65:255–263. doi:10.1001/archgenpsychiatry.2007.43
Zarate CA, Singh JB, Carlson PJ et al (2007) Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot study. Bipolar Disord 9:561–570. doi:10.1111/j.1399-5618.2007.00530.x
Yildiz A, Vieta E, Leucht S, Baldessarini RJ (2011) Efficacy of antimanic treatments: meta-analysis of randomized, controlled trials. Neuropsychopharmacology 36:375–389. doi:10.1038/npp.2010.192
Saraiva L, Fresco P, Pinto E, Gonçalves J (2003) Isoform-selectivity of PKC inhibitors acting at the regulatory and catalytic domain of mammalian PKC-alpha, -betaI, -delta, -eta and -zeta. J Enzyme Inhib Med Chem 18:475–483. doi:10.1080/14756360310001603158
Mallinger AG, Thase ME, Haskett R et al (2008) Verapamil augmentation of lithium treatment improves outcome in mania unresponsive to lithium alone: preliminary findings and a discussion of therapeutic mechanisms. Bipolar Disord 10:856–866. doi:10.1111/j.1399-5618.2008.00636.x
Schou M (1976) Pharmacology and toxicology of lithium. Annu Rev Pharmacol Toxicol 16:231–243. doi:10.1146/annurev.pa.16.040176.001311
Tang P, Roldan G, Brasher PMA et al (2006) A phase II study of carboplatin and chronic high-dose tamoxifen in patients with recurrent malignant glioma. J Neurooncol 78:311–316. doi:10.1007/s11060-005-9104-y
Thompson DS, Spanier CA, Vogel VG (1999) The Relationship Between Tamoxifen, Estrogen, and Depressive Symptoms. Breast J 5:375–382
Nelson TJ, Cui C, Luo Y, Alkon DL (2009) Reduction of beta-amyloid levels by novel protein kinase C(epsilon) activators. J Biol Chem 284:34514–34521. doi:10.1074/jbc.M109.016683
Pacheco MA, Stockmeier C, Meltzer HY et al (1996) Alterations in phosphoinositide signaling and G-protein levels in depressed suicide brain. Brain Res 723:37–45
Coull MA, Lowther S, Katona CL, Horton RW (2000) Altered brain protein kinase C in depression: a post-mortem study. Eur Neuropsychopharmacol 10:283–288
Hrdina P, Faludi G, Li Q et al (1998) Growth-associated protein (GAP-43), its mRNA, and protein kinase C (PKC) isoenzymes in brain regions of depressed suicides. Mol Psychiatry 3:411–418
Soares JC, Chen G, Dippold CS et al (2000) Concurrent measures of protein kinase C and phosphoinositides in lithium-treated bipolar patients and healthy individuals: a preliminary study. Psychiatry Res 95:109–118
Pandey GN, Dwivedi Y, Kumari R, Janicak PG (1998) Protein kinase C in platelets of depressed patients. Biol Psychiatry 44:909–911
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Abrial, E., Lucas, G., Scarna, H. et al. A Role for the PKC Signaling System in the Pathophysiology and Treatment of Mood Disorders: Involvement of a Functional Imbalance?. Mol Neurobiol 44, 407–419 (2011). https://doi.org/10.1007/s12035-011-8210-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12035-011-8210-4